Edition:
United Kingdom

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

68.28USD
20 Sep 2018
Change (% chg)

$1.03 (+1.53%)
Prev Close
$67.25
Open
$67.36
Day's High
$68.58
Day's Low
$67.33
Volume
416,636
Avg. Vol
573,925
52-wk High
$118.61
52-wk Low
$60.22

Latest Key Developments (Source: Significant Developments)

Agenus Receives Milestone Payment From Incyte
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Agenus Inc ::AGENUS RECEIVES MILESTONE PAYMENT FROM INCYTE.AGENUS INC - PAYMENT OF $5M RECEIVED FOR INITIATION OF PHASE 1 TRIAL OF LAG-3 ANTIBODY.AGENUS - ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $505 MILLION IN POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES FROM INCYTE.  Full Article

Incyte Q2 Non-GAAP Earnings Per Share $0.27
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Incyte Corp ::INCYTE REPORTS 2018 SECOND QUARTER FINANCIAL RESULTS AND UPDATES ON KEY CLINICAL PROGRAMS.Q2 NON-GAAP EARNINGS PER SHARE $0.27.TOTAL PRODUCT-RELATED REVENUES OF $421 MILLION IN Q2 2018, REPRESENTING 29 PERCENT GROWTH OVER SAME PERIOD LAST YEAR.Q2 EARNINGS PER SHARE VIEW $0.34 -- THOMSON REUTERS I/B/E/S.SEES 2018 NON-GAAP RESEARCH AND DEVELOPMENT EXPENSE $1,008 - $1,103 MILLION.  Full Article

Incyte, Merck Provide Update On Phase 3 Study
Friday, 6 Apr 2018 

April 6 (Reuters) - Incyte Corp ::INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA.INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA.STUDY'S SECOND PRIMARY ENDPOINT OF OVERALL SURVIVAL ALSO IS NOT EXPECTED TO REACH STATISTICAL SIGNIFICANCE.BASED ON RESULTS, AND AT RECOMMENDATION OF EDMC, PHASE 3 STUDY WILL BE STOPPED.252 WAS CONSISTENT WITH THAT OBSERVED IN STUDIES OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA.252 STUDY EVALUATING EPACADOSTAT WITH KEYTRUDA DETERMINED STUDY DID NOT MEET PRIMARY ENDPOINT.  Full Article

Incyte Corp Q4 Loss Per Share $0.71
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Incyte Corp ::INCYTE REPORTS 2017 FOURTH-QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL GUIDANCE AND UPDATES ON KEY CLINICAL PROGRAMS.Q4 REVENUE ROSE 36 PERCENT TO $444 MILLION.Q4 LOSS PER SHARE $0.71.Q4 EARNINGS PER SHARE VIEW $-0.45, REVENUE VIEW $426.0 MILLION -- THOMSON REUTERS I/B/E/S.INCYTE - IN 2018 CO TO BEGIN REPORTING CERTAIN NON-GAAP FINANCIAL MEASURES, TO BE CONSIDERED IN CONJUNCTION WITH CO'S GAAP REPORTING.QTRLY NON-GAAP NET INCOME WAS $4 MILLION.  Full Article

Syros Pharmaceuticals Enters Amendment To Stock Purchase Agreement With Incyte
Wednesday, 31 Jan 2018 

Jan 31 (Reuters) - Incyte Corp ::SYROS PHARMACEUTICALS -‍ ON JAN 31, ENTERED AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT WITH INCYTE TO FACILITATE PRIVATE PLACEMENT - SEC FILING​.SYROS PHARMACEUTICALS - ‍PURSUANT TO AMENDMENT INCYTE AGREED TO BUY 125,656 SHARES OF CO'S COMMON STOCK FOR $1.2 MILLION IN CASH IN PRIVATE PLACEMENT​.  Full Article

Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Incyte Corp ::INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT.INCYTE-‍UNDER AGREEMENT, SYROS TO USE ITS GENE CONTROL PLATFORM TO IDENTIFY NOVEL THERAPEUTIC TARGETS WITH FOCUS IN MYELOPROLIFERATIVE NEOPLASMS​.INCYTE - CO TO HAVE EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE ANY THERAPIES UNDER COLLABORATION THAT MODULATE VALIDATED TARGETS​.INCYTE - UNDER DEAL, CO TO GET OPTIONS TO GET EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM COLLABORATION FOR UP TO SEVEN VALIDATED TARGETS.INCYTE CORP - ‍ UNDER TERMS , CO TO PAY SYROS $10 MILLION UPFRONT AND PURCHASE A TOTAL OF $10 MILLION IN SYROS COMMON STOCK AT $12.61 PER SHARE​.INCYTE - SHOULD INCYTE EXERCISE ALL OF ITS OPTIONS UNDER DEAL, SYROS COULD GET UP TO $54 MILLION FROM INCYTE IN TARGET SELECTION & OPTION EXERCISE FEES.INCYTE CORP - SYROS COULD ALSO RECEIVE UP TO $50 MILLION IN DEVELOPMENT AND REGULATORY MILESTONES, AS WELL AS UP TO $65 MILLION IN COMMERCIAL MILESTONES.INCYTE CORP - SYROS WOULD ALSO BE ELIGIBLE TO RECEIVE LOW SINGLE-DIGIT ROYALTIES ON SALES OF PRODUCTS RESULTING FROM COLLABORATION.  Full Article

Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER.IMMUNOVACCINE INC - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL​ SHOW A 70% DISEASE CONTROL RATE DATA.IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018.IMMUNOVACCINE - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVAC​DEMONSTRATE TOLERABLE SAFETY PROFILE.  Full Article

Incyte initiates clinical trial of Ruxolitinib for treatment of essential thrombocythemia
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Incyte Corp :Incyte announces initiation of pivotal clinical trial of Ruxolitinib (Jakafi®) for the treatment of essential thrombocythemia.Incyte Corp - ‍announced that first patient has been treated in reset pivotal trial evaluating Ruxolitinib​.  Full Article

Incyte says Q3 earnings per share $0.17
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Incyte Corp -:Incyte reports 2017 third-quarter financial results and updates on key clinical programs.Q3 revenue $382 million versus I/B/E/S view $360.2 million.Q3 earnings per share $0.17.Q3 earnings per share view $0.07 -- Thomson Reuters I/B/E/S.Incyte Corp- for the quarter ended September 30, 2017, total revenues were $382 million as compared to $269 million for the same period in 2016.Incyte Corp - co updated FY 2017 financial guidance‍​.Incyte Corp now sees FY 2017 Jakafi net product revenues in a range of $1,125 million to $1,135 million versus prior view of $1,090 million to $1,120 mln‍​.Incyte Corp - reaffirms Iclusig net product revenues FY 2017 guidance.  Full Article

Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Incyte Corp :Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer.Incyte - ‍phase 3 trial evaluating Imfinzi and epacadostat in patients with unresectable non-small cell lung cancer is expected to begin in first-half 2018​.  Full Article

UPDATE 1-Lilly's lupus treatment succeeds in mid-stage trial

June 13 Eli Lilly & Co said on Wednesday its drug to treat autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a bigger study later this year.